Danish drug company Novo Nordisk says it has signed an agreement to set up a major research alliance with Chinese scientists.
The deal between Novo Nordisk and the Chinese Academy of Science establishes a joint research foundation in China, to be called the Novo Nordisk-Chinese Academy of Science Research Foundation. Its role will be to fund “activities of common interest within the fields of diabetes and biopharmaceuticals”, including related disciplines and technologies such as protein chemistry, immunology, inflammation, toxicology, oncology, endocrinology and drug delivery.
CAS vice-president Prof Chen Zhu said: “Chinese and Danish scientists share a history of excellent collaborations, which the new foundation will further strengthen” and noted that Novo Nordisk is recognised in China for its role in preventing and treating diabetes. The latter firm will provide US$2m in funding for the alliance.
Novo Nordisk has been active in China for some time. In January 2002 it established “a world-class R&D centre” in Beijing, claimed to be the first such facility to be established by international biopharmaceutical companies in China.